13:48 , Jan 3, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Liver cancer Cell culture and mouse studies suggest inhibiting the HMG-CoA reductase/SQLE/LSS pathway could help treat p53-deficient liver cancer. In human liver adenocarcinoma cell lines, levels of two metabolic intermediates biosynthesized by the pathway...
20:24 , Oct 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer; infectious disease

INDICATION: Cancer; melanoma; cervical cancer; influenza virus Mouse and monkey studies suggest simvastatin could be used as an adjuvant to boost the efficacy of cancer and influenza vaccines. In mice, immunization with the antigen ovalbumin...
19:50 , Jul 6, 2018 |  BC Extra  |  Preclinical News

New uses for marketed drugs in tough-to-treat indications

Two studies in Science Translational Medicine suggest three generics could be repurposed for difficult to treat indications. A paper from University of Edinburgh researchers showed that endothelial cell-targeted drugs simvastatin and perindopril could help treat...
15:16 , May 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Hypertension Cell culture and rat studies suggest nanoparticles loaded with cerivastatin could help treat pulmonary arterial hypertension (PAH) without the cytotoxicity of free cerivastatin. In a rat model of PAH, intratracheal administration of liposomes...
16:08 , Aug 11, 2017 |  BC Week In Review  |  Clinical News

Esperion's bempedoic acid combo meets in Phase II for hypercholesterolemia

Esperion Therapeutics Inc. (NASDAQ:ESPR) reported top-line data from the Phase II 1002-038 trial in 63 patients with hypercholesterolemia showing that the once-daily combination of 180 mg bempedoic acid (ETC-1002)/10 mg Zetia ezetimibe plus 20 mg...
00:16 , Aug 9, 2017 |  BC Extra  |  Clinical News

Esperion to raise funds after reporting bempedoic acid LDL-C data

Esperion Therapeutics Inc. (NASDAQ:ESPR) proposed to raise $150 million in a follow-on after market close on Tuesday following its announcement earlier in the day that oral bempedoic acid (ETC-1002)/ Zetia ezetimibe plus Lipitor atorvastatin met...
23:33 , Jul 13, 2017 |  BC Innovations  |  Strategy

Everyone counts in GWAS

The debate about the value of genome-wide association studies (GWAS) took a new twist with a Cell publication showing complex traits such as height and schizophrenia are controlled by broad, interconnected swaths of the genome...
07:00 , Jul 25, 2016 |  BC Week In Review  |  Company News

AstraZeneca, Shionogi endocrine/metabolic news

The U.S. District Court for the District of Columbia denied a motion from AstraZeneca seeking a temporary restraining order to prevent FDA from approving generic versions of Crestor rosuvastatin. After the ruling, Mylan N.V. (NASDAQ:MYL,...
07:00 , Jul 20, 2016 |  BC Extra  |  Company News

AZ facing more generic Crestor competition

On Tuesday, a federal judge in the U.S. District Court for the District of Columbia denied a motion from AstraZeneca plc (LSE:AZN; NYSE:AZN) seeking a temporary restraining order to prevent FDA from approving generic versions...
07:00 , May 9, 2016 |  BC Week In Review  |  Clinical News

Rosuvastatin regulatory update

FDA granted final approval to an ANDA from Allergan for a generic version of cholesterol drug Crestor rosuvastatin. The company launched the generic HMG-CoA reductase inhibitor in the U.S. It is approved to treat patients...